

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

### Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

#### Stakeholder list

<b>Manufacturer(s)</b> Grifols UK Limited Biohit HealthCare Ltd Theradiag R-Biopharm Sanqin Diagnostics Services B.V.
<b>Manufacturer(s) of related technologies (not included in scope)</b> Alpha Laboratories Ltd
<b>Professional groups</b> Association for Clinical Biochemistry and Laboratory Medicine British Society for Rheumatology Royal College of Physicians
<b>Patient/carer groups</b> National Rheumatoid Arthritis Society
<b>Research groups</b> None
<b>Associated guideline groups</b> None
<b>A provider of NHS services in England</b> Cambridge Life Sciences Ltd
<b>External Assessment Group</b> Peninsula Technology Assessment Group (PenTAG)
<b>Others</b> AbbVie Ltd Amgen Ltd Department of Health Healthcare Improvement Scotland NHS England NHS Greater Manchester Health and Care Commissioning Roche Products Ltd Pfizer Ltd UCB Pharma Ltd Welsh Government

**Definitions:**Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).